



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Frontiers Production Office
✉ production.office@frontiersin.org

RECEIVED 22 March 2024
ACCEPTED 22 March 2024
PUBLISHED 16 April 2024

CITATION
Frontiers Production Office (2024) Erratum:
Effects of imipramine on cancer patients
over-expressing Fascin1; description of the
HITCLIF clinical trial.
Front. Oncol. 14:1405306.
doi: 10.3389/fonc.2024.1405306

COPYRIGHT
© 2024 Frontiers Production Office. This is an
open-access article distributed under the terms
of the [Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction
in other forums is permitted, provided the
original author(s) and the copyright owner(s)
are credited and that the original publication
in this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Erratum: Effects of imipramine on cancer patients over-expressing Fascin1; description of the HITCLIF clinical trial

Frontiers Production Office*

Frontiers Media SA, Lausanne, Switzerland

KEYWORDS

cancer, metastasis, colorectal cancer, breast cancer, imipramine, Fascin1, tumor invasion, histology

An Erratum on

[Effects of imipramine on cancer patients over-expressing Fascin1; description of the HITCLIF clinical trial](#)

by Asensi-Cantó A, Rodríguez-Braun E, Beltrán-Videla A, Hurtado AM and Conesa-Zamora P (2023). *Front. Oncol.* 13:1238464. doi: 10.3389/fonc.2023.1238464

Due to a production error, the article type of this article mislabeled as Clinical Trial. The correct article type is Study Protocol.

The publisher apologizes for this mistake.

The original version of this article has been updated.

The publisher apologizes for this mistake. The original version of this article has been updated.